Drug Trial Radar · NCT06251024
Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,541
Actual
Start
Apr 2, 2024
Primary completion
Mar 11, 2025
Study completion Mar 11, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate for the prevention of lower respiratory tract disease (LRTD) due to RSV. The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to receive a single intra-muscular (IM) administration of either a pre-determined dose of the RSV vaccine candidate or placebo.
Conditions
- Respiratory Syncytial Virus Infection
- Healthy Volunteers
Interventions
RSV vaccine candidateBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
PlaceboBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of the first episode of RSV-LRTD (RSV A and/or RSV B) ≥ 14 days after vaccinationTime frame: ≥ 14 days after vaccination
Locations
25 sites in 6 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0360005
Norwood, Australia
Investigational Site Number : 0360003
Botany, New South Wales, Australia
Investigational Site Number : 0360004
Sippy Downs, Queensland, Australia
Investigational Site Number : 0360001
Southport, Queensland, Australia
Investigational Site Number : 0360002
Camberwell, Victoria, Australia
Investigational Site Number : 1520002
Santiago, Chile
Investigational Site Number : 1520008
Santiago, Chile
Investigational Site Number : 1520006
Concepción, Biobio, Chile
Investigational Site Number : 1520005
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1700004
Aguazul, Colombia
Investigational Site Number : 1700002
Barranquilla, Colombia
Investigational Site Number : 1700006
Bogotá, Colombia
Investigational Site Number : 1700007
Cali, Colombia
Investigational Site Number : 1700003
Girardot, Colombia
Investigational Site Number : 1700005
Ibague, Colombia
Investigational Site Number : 1700001
Quindío, Colombia
Investigational Site Number : 2140001
Santo Domingo, Dominican Republic
Investigational Site Number : 2140002
Santo Domingo, Dominican Republic
Investigational Site Number : 3400001
San Pedro Sula, Honduras
Investigational Site Number : 3400003
Tegucigalpa, Honduras
Investigational Site Number : 3400002
Tegucugalpa, Honduras
Investigational Site Number : 4840003
Querétaro, Mexico
Investigational Site Number : 4840002
León, Guanajuato, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.